Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Peregrine Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Equity Offering 15
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 22
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 23
Peregrine Pharmaceuticals Inc – Key Competitors 25
Peregrine Pharmaceuticals Inc – Key Employees 26
Peregrine Pharmaceuticals Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Strategy And Business Planning 28
Jul 31, 2017: Peregrine Provides Strategic Update 28
Financial Announcements 30
Sep 11, 2017: Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 and Recent Developments 30
Jul 14, 2017: Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments 32
Mar 13, 2017: Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments 35
Dec 12, 2016: Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2017 and Recent Developments 37
Sep 08, 2016: Peregrine Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2017 and Recent Developments 39
Jul 14, 2016: Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2016 and Recent Developments 41
Mar 09, 2016: Peregrine Pharmaceuticals Reports Financial Results for Third Quarter of Fiscal Year 2016 and Recent Developments 43
Corporate Communications 45
Oct 24, 2017: Peregrine Pharmaceuticals Announces Appointment of Patrick Walsh to Board of Directors of Peregrine and Avid Bioservices 45
Oct 19, 2017: Peregrine Pharmaceuticals Announces Appointment of Mark R. Bamforth to Board of Directors of Peregrine and Avid Bioservices 46
Sep 11, 2017: Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D. as President of Avid Bioservices 47
Aug 11, 2017: Peregrine Announces Measures to Reduce Costs, Facilitate Profitability and Strengthen its Operations 48
Product News 49
09/06/2016: National Comprehensive Cancer Network Awards Three Grants for Combination Studies of Peregrine Pharmaceuticals Bavituximab in Multiple Cancers 49
May 01, 2017: MilliporeSigma’s Mobius 2,000-liter Single-use Bioreactors to Expand Avid Bioservices’ Manufacturing Capabilities 50
01/20/2016: Peregrine Pharmaceuticals to Present at Two Upcoming Cancer Immunotherapy Conferences 51
Clinical Trials 53
Nov 14, 2016: New Study Demonstrates Anti-Tumor Advantages for Combination Treatment Featuring Peregrine Pharmaceuticals PS-Targeting Antibodies in a Preclinical Melanoma Model 53
Oct 24, 2016: Preclinical Research Demonstrates Peregrine Pharmaceuticals’ PS-Targeting Antibodies Enhance the Anti-Tumor Activity of PD-L1 Checkpoint Inhibitors in Model of Triple Negative Breast Cancer 55
Oct 10, 2016: Peregrine Pharmaceuticals Reports Top-Line and Initial Biomarker Data from Phase III SUNRISE Trial of Bavituximab in Oral Presentation at European Society for Medical Oncology (ESMO) 2016 Congress 56
Sep 27, 2016: Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer 58
Sep 21, 2016: Peregrine Pharmaceuticals Provides Update on Oral Presentation of Top-Line Data from Phase III SUNRISE Trial of Bavituximab at European Society for Medical Oncology (ESMO) 2016 Congress 59
Apr 20, 2016: Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC) 60
Feb 25, 2016: Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab 61
Jan 11, 2016: Peregrine Pharmaceuticals Provides Update on Planned Expansion of Bavituximab Clinical Program in Lung, Breast and Other Cancers 62
Other Significant Developments 64
Jun 02, 2016: Peregrine Pharmaceuticals Provides Corporate Update Highlighting Latest Developments for Contract Manufacturing and Drug Development Businesses 64
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Peregrine Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Peregrine Pharmaceuticals Inc, Medical Devices Deals, 2011 to YTD 2017 10
Peregrine Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Peregrine Pharma Enters into Research Agreement with National Comprehensive Cancer Network 12
Peregrine Pharma Expands its Agreement with AstraZeneca 13
Peregrine Pharma Enters into Research Agreement with Memorial Sloan Kettering Cancer Center 14
Peregrine Pharma to Raise USD30 Million in Public Offering of Shares 15
Peregrine Pharma to Raise USD12.3 Million in Public Offering of Shares 16
Peregrine Pharma Completes Underwriters Exercise Of Partial Over-Allotment Option Of Public Offering Of Series E Preferred Stock For US$19.4 Million 17
Peregrine Pharma Files Registration Statement For Public Offering Of Securities For US$100 Million 19
Peregrine Pharma Completes Private Placement Of Shares For US$14 Million 20
Peregrine Pharma Files Registration Statement For Private Placement Of Common Stock For US$75 Million 21
Peregrine Pharma Completes Private Placement Of Shares For US$7 Million 22
Peregrine Pharma Completes Second Tranche Of Public Offering Of Common Stock For US$2.35 Million 23
Peregrine Pharmaceuticals Inc, Key Competitors 25
Peregrine Pharmaceuticals Inc, Key Employees 26
Peregrine Pharmaceuticals Inc, Subsidiaries 27